Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma xenograft models that coexpressed BCL-XL or MCL-1 with BCL-2 were also resistant to venetoclax.
|
26939706 |
2016 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma (MM) is a slow-growing malignancy whose plasma cells express the BCL-2 antiapoptosis gene.
|
7743552 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 mediated suppression of apoptosis in myeloma NS0 cultures.
|
10812183 |
2000 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 antisense therapy with G3139 (oblimersen sodium; Genasense, Genta Inc, Berkeley Heights, NJ) is in clinical trials for a number of malignancies, including an ongoing trial in myeloma.
|
12720156 |
2003 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 mRNA was significantly higher in the bone marrow mononuclear cells from MM patients.
|
30170425 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions.
|
30594434 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma patients with the t(11;14) translocation who acquire resistance due to co-expression of Mcl-1 and Bcl-xL.
|
29761903 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accelerated plasmacytomagenesis in strain C.BCL2 may be useful for designing and testing BCL2 inhibition strategies in human plasma cell tumors overexpressing BCL2, such as Waldenström's macroglobulinemia and multiple myeloma.
|
14695177 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, the identification of a subset of cell lines and primary cells effectively killed by ABT-737 alone supported the evaluation of ABT-263, an orally active counterpart to ABT-737, for the treatment of t(11;14) and hyperdiploid groups of myeloma harboring a Bcl-2(high)/Mcl-1(low) profile.
|
21835956 |
2011 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Approximately, 20% of myeloma patients will exhibit <i>t</i> (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option.
|
30428277 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As wogonin was effective in vitro in promotion of apoptosis of myeloma cell by Akt-modulated, Bax and Bcl-2 related intrinsic apoptotic pathway, wogonin may be a potential therapeutic agent against multiple myeloma.
|
23142241 |
2013 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM.
|
28356941 |
2017 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD34(+) cells were resistant to Ad-p53-mediated apoptosis, and CFU-GM and BFU-E colony formation was not affected by treatment with Ad-p53.Ad-p53 is a potent inducer of apoptosis in MM cell lines and in freshly isolated myeloma cells expressing low levels of bcl-2.
|
11146157 |
2000 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-culture experiments resulted in MDSC-induced AMPK phosphorylation in MM cells, which was associated with an increase in the anti-apoptotic factors MCL-1 and BCL-2, and the autophagy-marker LC3II.
|
30419344 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the protective effects of bcl-2 in MM cells act upstream in the NF-kappaB activation-signaling pathway and the potential use of NF-kappaB as a biomarker in progressive MM.
|
10216101 |
1999 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conversely, suppression of Bcl-2 enhanced the chemosensitivity of myeloma cells in vitro.
|
15085157 |
2004 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Disruption of the intrinsic apoptotic pathway by BCL2 and MCL1 upregulation is observed in >80% of myeloma cases and is associated with an aggressive clinical course.
|
24236538 |
2014 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ex vivo pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat led to significantly lower MM cell proliferation and increased apoptosis and diminished expression of c-MYC and BCL-2.
|
31015208 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression.
|
30409700 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of bcl-2 in 8226 and ARP-1 multiple myeloma (MM) cell lines expressing relatively low levels of bcl-2, resulted in 1-2 log increase in resistance to dexamethasone (DEX)-induced apoptosis.
|
9454907 |
1998 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines.
|
10557057 |
1999 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
G3139 can consistently enter myeloma cells, downregulate the expression of Bcl-2, and enhance the efficacy of myeloma therapy.
|
12529680 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.
|
27465916 |
2016 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High BCL2 levels have been detected in most human lymphoid malignancies, not limited to follicular lymphoma (where the role of BCL2 overexpression is driven by the t[14;18] translocation) but also B-cell chronic lymphocytic leukemia (CLL) and multiple myeloma.
|
24095849 |
2014 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression.
|
30076373 |
2018 |